accession therapeutics

Creating the ideal oncotherapy: a universal cancer bispecific platform

Prof. Bent Jakobsen

bent.jakobsen@accessiontherapeutics.com CEO and Founder

Our team - experienced from research to clinic



Prof Bent Jakobsen

CEO and Founder

25 years as an Immunotherapy pioneer. Scientific Founder of two unicorns: Adaptimmune Ltd & Immunocore Ltd



Prof Alan Parker Chief Scientific Officer, Trocept Therapeutics



Dr Dave Cole Head of Molecular Science



Dr Jez Gerry Head of Preclinical Development

Translated >10 innovative research projects from PoC to regulatory submissions and clinical trials

Our in-depth bios can be found at: www.accessiontherapeutics.com/our-team



Andy Johnson

Head of CMC

Head of Translational science

Quality and Regulatory




Ranjeet BabbraNick CrossHead of Quality AssuranceCFO and Chairman



Prof Hardev Pandha Medical Director







0

.

.

0

•

•

0


.

•

.

.


Accession has developed a universal bispecific that targets all cancer cells to address tumor diversity...




Solution: a universal bispecific that targets all cancer cells



...recruiting T cells into the tumor and potently redirecting tumor killing




Universal bispecific recruits T cells into the tumor and potently redirects tumor killing





Potential to kill any tumor cell regardless of antigen profile





Problem 2: This type of potent therapy must only be in the tumor



•

•

0

.

0

.

.

0

.

.

Accession has developed a unique tumor-localizing viral platform for I.V. delivery

Solution: Accession has a unique viral delivery system that enables its universal bispecific to be only expressed in, and secreted from, tumor cells

Bispecific is only expressed in the tumor

.

Problem 2: This type of potent therapy must only be in the tumor




trocept is a virus uniquely engineered not to infect normal cells

- only capable of infecting cancer cells



trocept first-in-class I.V. delivery of tumor disrupting drugs - overcoming the limitations of existing viral platforms



Unique

Does not target healthy cells

Directed


Cancer specific targeting


Amplifies broad tumor activity

Potent



Wildtype Ad5 infects normal cells








😢 Wildtype Ad5

infects normal cells, mostly the liver, reducing viral bioavailability for tumors





trocept vis engineered (Mods.1-3) not to infect normal cells





Wildtype Ad5 infects normal cells and provides limited protection






😢 Wildtype Ad5

infects normal cells, mostly the liver, reducing tumor efficacy



trocept 🕢 localizes to tumors (Mod.4) achieving 100% survival





trocept is engineered to bind $\alpha \vee \beta 6$ integrin, a cancer specific marker highly expressed on several indications

Carcinoma	*Incidence/year	*Deaths/year	*10 year survival %	% positive tumors
Pancreas	9,618	8,817	<]	91
Head & Neck	5,550	5,091	N/A	80-100
Stomach	6,682	4,576	15	84
Serous ovarian	2,500	1,000	15	60-100
Basal cell	60,000	450	70	75
Liver	6,214	5,635	20	70
Oesophagus	8,919	7,790	12	68
Cervical squamous	8,919	7,790	12	59
Lung	46,403	35,895	5	46
Endometrial	9,703	2,409	72	42
Breast	55,222	11,433	78	31
Kidney	12,593	4,421	50	21
Colon	41,265	15,903	57	31

*UK figures (CRUK)




In house target validation confirms $\alpha \nu \beta 6$ integrin expression in cancers with high unmet need

Carcinoma	*Incidence / year	*10 year survival %	Approved CPI ORR (%)	% positive tumours (in-house IHC)
Head & Neck	12,422	N/A	15%	100
Pancreas	10,452	5	N/A	100
Gastric	6,453	17	15%	84
Ovarian	7,495	35	N/A	100
NSCLC	48,549	10	55%	87
Colon	42,866	53	N/A	86

Target validation data generation continues









Specific in tumor oncotherapy

Program: Trocept one

Stage: Pre-Clinical

Disease Area: Immuno-oncology

Indications: Epithelial origin carcinomas (inc. oesophageal, pancreatic, lung, breast, ovarian, kidney, stomach, colon, head & neck)

MoA : Viral targeting via a cancer specific marker ($\alpha v \beta 6$ integrin), turning infected cancer cells into drug factories, generating high doses of cancer localized immunotherapies to disrupt solid tumors

Description: *Trocept one* uses Accession's engineered adenovirus viral delivery platform (trocept) to generate high doses of immunotherapies directly within the tumor following systemic I.V. delivery. *Trocept one* only infects specific cancer cells, avoiding healthy tissue with reduced immunogenicity. Infected cancer cells then amplify a broad therapeutic response by secreting immunotherapies only in the tumor, creating highly potent *in tumor* activity.








- Trocept one: in tumor delivery of immune checkpoint inhibitors
 - Addresses dose limiting toxicity and turns cold tumors hot
 - Could improve response rates in a highly attractive therapeutic area
- Rapid development into the clinic (1H 2024)
- Clinical validation of the **Trocept** virus, demonstrating safety, I.V. delivery, tumor targeting, replication and payload production





Generation of functional ICIs by **trocept one** infected cancer cells




High yields of ICIs generated

ICIs are fully functional in cell assays




Pipeline: parallel development of fully differentiated clinical candidates





Partnerships and collaborations



Accession is interested in early stage partnerships



Trocept could deliver partner nominated transgenes



Contact details



Prof Bent Jakobsen

CEO and Founder Email: bent.Jakobsen@ accessiontherapeutics.com

Website: www.accessiontherapeutics.com



Dr Dave Cole Head of Molecular Science Email: dave.cole@ accessiontherapeutics.com



Ranjeet Babbra Head of Quality Assurance

Email: ranjeet.babbra@ accessiontherapeutics.com



